Patients with colon cancer and obesity treated with GLP-1 receptor agonists (GLP-1RA) had lower mortality compared to other patients[3]. A retrospective cohort study showed a similar trend even with a lower incidence of serious non-cancer complications[1]. In patients with type 2 diabetes without cancer at baseline, GLP-1RAs were associated with a lower risk of colorectal cancer compared to insulin[1][2]. The likelihood of developing colon cancer was 44% lower in GLP-1RA users compared to insulin users[2]. Among approximately 22,600 people on insulin, there were 167 cases of colon cancer, compared to only 94 cases in the same number on GLP-1RA[2]. A study indicates a positive effect of these drugs on patients with obesity and colon cancer[3].